Novel clinical treatments for pancreatic cancer are now available to medically eligible patients at Winthrop in a Phase II clinical study. Winthrop is one of only seven sites, nationally, to offer an immunotherapy protocol for pancreatic cancer, based on an innovative technique.
Patients with inoperable pancreatic cancer, both locally advanced and metastatic, may be eligible for the trial of this new, first line therapy. The treatment involves removing the patient’s lymphocytes, or immune-effector cells, and activating them, in the laboratory environment, with the immune cells of a healthy individual. The new mixture, or cytoimplant, is then injected into the patient’s primary tumor. The goal is to stimulate a reaction against the primary tumor and its metastatic sites.
Frank Gress, MD, Director of the Endoscopic Ultrasound Center for Diagnostic and Therapeutic Intervention, Division of Gastroenterology, Hepatology, and Nutrition, and Jeffrey G. Schneider, MD, Faculty Attending, Division of Oncology/Hematology, are the clinical co-investigators. For further information, call Diane Redmond, CCRA, Data Coordinator, Division of Oncology-Hematology, at (516) 663-4611.